Cerus Corporation is a biomedical products company dedicated to safeguarding the world's blood supply. Headquartered in Concord, California, Cerus develops and commercializes the INTERCEPT Blood System, designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites that may be present in donated blood components. The INTERCEPT system is used for platelets, plasma, and, in some regions, red blood cells, enhancing the safety of blood transfusions for patients worldwide. The company focuses on innovation in blood safety technology and works with blood centers, hospitals, and regulatory authorities globally.
The Concord headquarters serves as the primary center for corporate leadership, research and development, administrative operations, and strategic planning for Cerus's global activities.
The facility likely includes advanced R&D laboratories for developing and testing blood safety technologies, along with modern office spaces designed to foster collaboration and innovation.
Cerus fosters a work culture centered on scientific excellence, patient safety, and a mission-driven approach to public health. Employees are typically engaged in highly specialized roles requiring expertise in biomedical sciences, engineering, and regulatory affairs.
The headquarters is crucial for advancing Cerus's core mission of blood safety, coordinating global product development and distribution, and driving innovation in transfusion medicine.
Cerus Corporation has a significant global presence, with its INTERCEPT Blood System used in numerous countries across North America, Europe, the Middle East, Africa, Asia, and Latin America. Their global functions include direct sales and distribution in key markets, partnerships with regional distributors, clinical and technical support for blood centers and hospitals, and ongoing engagement with international regulatory bodies to expand product approvals and adoption worldwide.
1220 Concord Avenue
Concord
CA
USA
Address: Printerweg 22, 3821 AD Amersfoort, The Netherlands
To facilitate the commercialization and support of Cerus's blood safety products across Europe and adjacent regions, ensuring compliance with regional regulations and meeting the needs of local blood centers and hospitals.
Address: Specific address not publicly detailed, functions may be remote or co-located.
To navigate the U.S. regulatory landscape, advocate for blood safety policies, and collaborate with federal agencies and healthcare policy makers.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cerus Corporation' leadership includes:
Cerus Corporation has been backed by several prominent investors over the years, including:
Cerus Corporation announced a significant CEO succession plan in May 2024, with William 'Obi' Greenman planning to retire by year-end and Vivek K. Jayaraman designated as his successor. The company also strengthened its human resources leadership with a new Chief People Officer appointment in early 2024.
Discover the tools Cerus Corporation uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cerus Corporation commonly uses the [first_initial][last]@cerus.com email format. For example, an employee named Jane Doe would likely have the email address jdoe@cerus.com. Other less common formats might exist for specific departments or legacy systems.
[first_initial][last]@cerus.com
Format
jdoe@cerus.com
Example
90%
Success rate
GlobeNewswire • May 7, 2024
Cerus Corporation announced its financial results for the first quarter ended March 31, 2024. Product revenue was $37.3 million, a decrease of 13% compared to the prior year period, primarily due to ordering patterns from BARDA for INTERCEPT 7-day platelets. The company highlighted ongoing global adoption and reaffirmed its full-year 2024 product revenue guidance....more
GlobeNewswire • May 7, 2024
Cerus Corporation announced that William M. “Obi” Greenman will retire as President and Chief Executive Officer and as a member of the Board of Directors, by the end of 2024. Vivek K. Jayaraman, the Company’s Chief Operating Officer, has been appointed President, INTERCEPT, and designated by the Board to succeed Mr. Greenman as President and CEO upon his retirement....more
GlobeNewswire • January 9, 2024
Cerus Corporation announced the appointment of Chrissy S. Smith as Chief People Officer. Ms. Smith brings over two decades of human resources leadership experience in the life sciences industry and will oversee all aspects of Cerus’ global human resources function....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cerus Corporation, are just a search away.